The company has retained the financial advisory firm Seven Hills Partners to help it to explore the various alternatives for the future of the company.
“Our objective is to identify an option that will allow us to provide continuing innovation and high-value offerings to our customers, a stimulating environment for our employees, and a solid investment for our shareholders,” said Dr John McAlister, president and CEO of Tripos.
Tripos recently announced that it is streamlining its discovery research business after its four-year $90 million file enrichment project with Pfizer expired. The streamlining is expected to result in job losses, principally at the company’s UK facility.